Cipla acquires monoclonal antibodies maker Mabpharm

To further consolidate its position in biosimilars market, Cipla Ltd has taken over Mabpharm Private Limited, in which it was holding 25% stake. Cipla Ltd has informed BSE that Meditab Specialities Private Limited, a wholly owned subsidiary of the company, has acquired 75% stake in Mabpharm.
 
Consequent to the acquisition of the aforesaid stake, Mabpharm has now become a wholly-owned subsidiary of Cipla. Mabpharm is inter alia engaged in development of monoclonal antibodies for treatment of cancer and auto-immune diseases.